



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:

FANG FANG

Serial No.: 09/555,446

Filed: AUGUST 16, 2000

Title: MULTIVALENT RECOMBINANT
ANTIBODIES FOR TREATING HRV
INFECTIONS

) Group Art Unit: To be assigned

) Examiner: To be assigned

)

)

)


)

)

)

Certificate of Express Mailing

I hereby certify that this correspondence and all marked
attachments are being deposited with the United States
Postal Service as "Express Mail" in an envelope
addressed to Honorable Commissioner of
Patents and Trademarks, Mail Stop Petition
Box 1450, Alexandria, VA 22313-1450
on August 18, 2003.


Suzanne L. Givens

RESPONSE TO COMMUNICATION REGARDING REVOCATION OF POWER
OF ATTORNEY AND NEW POWER OF ATTORNEY AND CHANGE OF
ADDRESS

Honorable Commissioner of
Patents and Trademarks
Mail Stop Petition
Box 1450
Alexandria, VA 22313-1450

RECEIVED

AUG 25 2003

OFFICE OF PETITIONS

Sir:

This communication is responsive to the June 19, 2002 Notice Regarding Power of Attorney communication from the United States Patent Office. The undersigned notes that Revocation of Power of Attorney and New Power of Attorney and Change of Address, filed May 28, 2002 was duly executed by Perlan Therapeutics, Inc. However, the Office objected to the Power, indicating that the Assignee indicated on the Power has not been recorded in the Office files. The undersigned notes that Assignee, CFY Biomedicals, Inc. as recorded with the Office (Reel 011155, Frame 0709) has change its name to Perlan Therapeutics, Inc. Enclosed is a copy of the



amended and Restated Articles of Incorporation of CFY Biomedicals, Inc. Consequently, the Revocation of Power of Attorney and New Power of Attorney and Change of Address, filed May 28, 2002 was executed in the corporation's current and accurate name, Perlan Therapeutics, Inc.

In view of the above, the undersigned respectfully request acceptance of the Revocation of Power of Attorney and New Power of Attorney and Change of Address document.

If questions arise relating to this petition, the Examiner is hereby invited to contact the undersigned to discuss the same.

Respectfully submitted,

PILLSBURY WINTHROP LLP

By: 

John R. Wetherell
Registration No. 31,678
Tel.: (858) 509-4022
Fax: (858) 509-4010

Attorney Ref. No.: 014357-0278749

PILLSBURY WINTHROP LLP
11682 El Camino Real, Suite 200
San Diego, CA 92130-2593

RECEIVED

AUG 2 5 2003

OFFICE OF PETITIONS

Please charge our deposit account in the amount of \$1,635.00, which includes the extensions of time fee and Petition to Review filing fee. If the fee submitted is incorrect or if any other fees are due in connection with this submission, please charge any such fee or credit any overpayment to Deposit Account No. 50-2212, Order No. **014357-0278749**.

Respectfully submitted,

PILLSBURY WINTHROP LLP

By: 

John R. Wethejell
Registration No. 31,678
Tel.: (858) 509-4022
Fax: (858) 509-4010

Attorney Ref. No.: 014357-0278749

PILLSBURY WINTHROP LLP
11682 El Camino Real, Suite 200
San Diego, CA 92130-2593

RECEIVED

AUG 2 5 57 00 J

OFFICE OF PETITIONS



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Application of:

FANG FANG

Serial No.: 09/555,446

Filed: AUGUST 16, 2000


Title: MULTIVALENT RECOMBINANT
ANTIBODIES FOR TREATING HRV
INFECTIONS

) Group Art Unit: To be assigned

)
) Examiner: To be assigned

) Certificate of Express Mailing

) I hereby certify that this correspondence and all marked
) attachments are being deposited with the United States
) Postal Service as "Express Mail" in an envelope
) addressed to Honorable Commissioner of
) Patents and Trademarks, Mail Stop Petition
) Box 1450, Alexandria, VA 22313-1450
) ~~or August 16, 2003~~


Suzanne Lloy Simpson


SEQUENCE LISTING TRANSMITTAL

Transmitted herewith in the above-identified application are the following documents:

1. Copy of Notice to Comply;
2. Amendment/Response to Notice to Comply;
3. Statement Under 37 CFR § 1.821(f) and (g);
4. Sequence Listing in computer readable format; and
5. Sequence Listing in paper format.

Respectfully submitted,

PILLSBURY WINTHROP LLP

By: 

John R. Wetherell
Registration No. 31,678
Tel.: (858) 509-4022
Fax: (858) 509-4010

Attorney Ref. No.: 014357-0278749

PILLSBURY WINTHROP LLP
11682 El Camino Real, Suite 200
San Diego, CA 92130-2593

Application No.: 09/555448**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other:

Applicant Must Provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support (SIRA)

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Application of:

FANG FANG

Serial No.: 09/555,446

Filed: AUGUST 16, 2000

Title: MULTIVALENT RECOMBINANT
ANTIBODIES FOR TREATING HRV
INFECTIONS

) Group Art Unit: To be assigned

) Examiner: To be assigned

) CERTIFICATE OF EXPRESS MAILING
) UNDER 37 C.F.R. §1.10

) I hereby certify that this correspondence and all marked
) attachments are being deposited with the United States
) Postal Service as "Express Mail" in an envelope
) addressed to Honorable Commissioner of
) Patents and Trademarks, Mail Stop Petition
) Box 1450, Alexandria, VA 22313-1450
) on August 18, 2003


Suzanne H. Simpson

TRANSMITTAL LETTER

Honorable Commissioner of
Patents and Trademarks
Mail Stop Petition
Box 1450
Alexandria, VA 22313-1450

Sir:

Transmitted herewith for filing are the following:

1. Petition to Revive Unintentionally Abandoned Application;
2. Reply/Amendment/Letter;
3. Response to Office Communication;
4. Response to Communication regarding Revocation of Power of Attorney and
New Power of Attorney and Change of Address; and
5. Return Postcard.

RECEIVED

AUG 23 2003

OFFICE OF PETITIONS